These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 33724918)

  • 1. Therapeutic efficacy of 3,4-Diaminopyridine phosphate on neuromuscular junction in Pompe disease.
    Bragato C; Blasevich F; Ingenito G; Mantegazza R; Maggi L
    Biomed Pharmacother; 2021 May; 137():111357. PubMed ID: 33724918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen storage in a zebrafish Pompe disease model is reduced by 3-BrPA treatment.
    Bragato C; Carra S; Blasevich F; Salerno F; Brix A; Bassi A; Beltrame M; Cotelli F; Maggi L; Mantegazza R; Mora M
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165662. PubMed ID: 31917327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.
    Todd AG; McElroy JA; Grange RW; Fuller DD; Walter GA; Byrne BJ; Falk DJ
    Ann Neurol; 2015 Aug; 78(2):222-34. PubMed ID: 25925726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral nerve and neuromuscular junction pathology in Pompe disease.
    Falk DJ; Todd AG; Lee S; Soustek MS; ElMallah MK; Fuller DD; Notterpek L; Byrne BJ
    Hum Mol Genet; 2015 Feb; 24(3):625-36. PubMed ID: 25217571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
    Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
    J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Airway smooth muscle dysfunction in Pompe (
    Keeler AM; Liu D; Zieger M; Xiong L; Salemi J; Bellvé K; Byrne BJ; Fuller DD; ZhuGe R; ElMallah MK
    Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L873-L881. PubMed ID: 28336814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.
    Colella P; Sellier P; Gomez MJ; Biferi MG; Tanniou G; Guerchet N; Cohen-Tannoudji M; Moya-Nilges M; van Wittenberghe L; Daniele N; Gjata B; Krijnse-Locker J; Collaud F; Simon-Sola M; Charles S; Cagin U; Mingozzi F
    EBioMedicine; 2020 Nov; 61():103052. PubMed ID: 33039711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.
    Ziegler RJ; Bercury SD; Fidler J; Zhao MA; Foley J; Taksir TV; Ryan S; Hodges BL; Scheule RK; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2008 Jun; 19(6):609-21. PubMed ID: 18500944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adult form of Pompe disease].
    Ziółkowska-Graca B; Kania A; Zwolińska G; Nizankowska-Mogilnicka E
    Pneumonol Alergol Pol; 2008; 76(5):396-9. PubMed ID: 19003770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of Potent Mannose 6-Phosphate Analogues for the Functionalization of Lysosomal Enzymes To Improve the Treatment of Pompe Disease.
    El Cheikh K; Basile I; Da Silva A; Bernon C; Cérutti P; Salgues F; Perez M; Maynadier M; Gary-Bobo M; Caillaud C; Cérutti M; Garcia M; Morère A
    Angew Chem Int Ed Engl; 2016 Nov; 55(47):14774-14777. PubMed ID: 27774736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.
    Schaaf GJ; van Gestel TJM; In 't Groen SLM; de Jong B; Boomaars B; Tarallo A; Cardone M; Parenti G; van der Ploeg AT; Pijnappel WWMP
    Acta Neuropathol Commun; 2018 Nov; 6(1):119. PubMed ID: 30404653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.
    Kishnani PS; Corzo D; Nicolino M; Byrne B; Mandel H; Hwu WL; Leslie N; Levine J; Spencer C; McDonald M; Li J; Dumontier J; Halberthal M; Chien YH; Hopkin R; Vijayaraghavan S; Gruskin D; Bartholomew D; van der Ploeg A; Clancy JP; Parini R; Morin G; Beck M; De la Gastine GS; Jokic M; Thurberg B; Richards S; Bali D; Davison M; Worden MA; Chen YT; Wraith JE
    Neurology; 2007 Jan; 68(2):99-109. PubMed ID: 17151339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
    Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
    Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.
    Mantegazza R
    Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1013-1018. PubMed ID: 31639317
    [No Abstract]   [Full Text] [Related]  

  • 19. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
    Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.